Investor Login

VelosBio

← Back to Ventures Portfolio

VelosBio Inc. is a near-term clinical-stage biopharmaceutical company focused on novel cancer targets.

VelosBio

San Diego, CA

11.05.2020
VelosBio to be Acquired by Merck for $2.75 billion

Read More

10.22.2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-10…

Read More

logo_white
veteran_logo_white
NVCA
bio
nc-biotech